We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comprehensive comparison of the prognostic value of systemic inflammation biomarkers for cancer cachexia: a multicenter prospective study.
- Authors
Xie, Hailun; Ruan, Guotian; Wei, Lishuang; Zhang, Heyang; Ge, Yizhong; Zhang, Qi; Lin, Shiqi; Song, Mengmeng; Zhang, Xi; Liu, Xiaoyue; Yang, Ming; Tang, Meng; Song, Chun-Hua; Deng, Li; Shi, Hanping
- Abstract
Aims: Systemic inflammation plays an important role in cancer cachexia. However, among the systemic inflammatory biomarkers, it is unclear which has optimal prognostic value for cancer cachexia. Methods: The Kaplan–Meier method was used and the log-rank analysis was performed to estimate survival differences between groups. Cox proportional hazard regression analyses were conducted to assess independent risk factors for all-cause mortality. Results: The C-reactive protein-to-albumin ratio (CAR) was the optimal prognostic assessment tool for patients with cancer cachexia, with 1-, 3-, and 5-year predictive powers of 0.650, 0.658, and 0.605, respectively. Patients with a high CAR had significantly lower survival rates than those with a low CAR. Moreover, CAR can differentiate the prognoses of patients with the same pathological stage. Cox proportional risk regression analyses showed that a high CAR was an independent risk factor for cancer cachexia. For every standard deviation increase in CAR, the risk of poor prognosis for patients with cancer cachexia was increased by 20% (hazard ratio = 1.200, 95% confidence interval = 1.132–1.273, P < 0.001). Conclusions: CAR is an effective representative of systemic inflammation and a powerful factor for predicting the life function and clinical outcome of patients with cancer cachexia.
- Subjects
CACHEXIA; PROGNOSIS; TUMOR markers; CANCER prognosis; MORTALITY risk factors
- Publication
Inflammation Research, 2022, Vol 71, Issue 10/11, p1305
- ISSN
1023-3830
- Publication type
Article
- DOI
10.1007/s00011-022-01626-7